<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02766439</url>
  </required_header>
  <id_info>
    <org_study_id>201233-004</org_study_id>
    <nct_id>NCT02766439</nct_id>
  </id_info>
  <brief_title>Rhupus Syndrome and Efficacy of Etanercept Treatment</brief_title>
  <official_title>the First People's Hospital of Chenzhou</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yang Beibei</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First People's Hospital of Chenzhou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      between March 2013 and March 2014, Rhupus patients were enrolled to receive a 25-mg
      etanercept injection subcutaneously twice a week. The follow-up time of the study was 24
      weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      between March 2013 and March 2014, patients who were unresponsive to therapy with
      corticosteroid and disease-modifying antirheumatic drugs (DMARDs), with a Disease Activity
      Score in 28 Joints (DAS28) &gt;5.1 were enrolled to receive a 25-mg etanercept injection
      subcutaneously twice a week. The follow-up time of the study was 24 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Activity Score in 28 Joints (DAS28)</measure>
    <time_frame>24 week</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">6</enrollment>
  <condition>Rhupus Syndrome, Etanercept</condition>
  <arm_group>
    <arm_group_label>Rhupus syndrome, SLE without RA</arm_group_label>
    <description>Rhupus syndrome, SLE without RA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanercept</intervention_name>
    <description>25-mg etanercept injection subcutaneously twice a week</description>
    <arm_group_label>Rhupus syndrome, SLE without RA</arm_group_label>
    <other_name>TNFÐ° blockade</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients who were unresponsive to therapy with corticosteroid and disease-modifying
        antirheumatic drugs (DMARDs), with a Disease Activity Score in 28 Joints (DAS28) &gt;5.1 were
        enrolled
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Rhupus patients who were unresponsive to therapy with corticosteroid and
        disease-modifying antirheumatic drugs (DMARDs), with a Disease Activity Score in 28 Joints
        (DAS28) &gt;5.1

        Exclusion Criteria:

        - those who had participated in other studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2016</study_first_submitted>
  <study_first_submitted_qc>May 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2016</study_first_posted>
  <last_update_submitted>May 6, 2016</last_update_submitted>
  <last_update_submitted_qc>May 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>First People's Hospital of Chenzhou</investigator_affiliation>
    <investigator_full_name>Yang Beibei</investigator_full_name>
    <investigator_title>the First People's Hospital of Chenzhou</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

